期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HIV-1潜伏感染人Jurkat T细胞模型的建立 被引量：2

Establishment of a HIV-1 latent infection model in Jurkat T cell line
原文传递
导出
摘要 目的建立Ⅰ型艾滋病病毒(HIV-1)潜伏感染人Jurkat T细胞的模型,为进一步研究HIV-1潜伏感染机制奠定基础。方法利用一种表达增强型绿色荧光蛋白(EGFP)的HIV-1假病毒感染人Jurkat T细胞,采用流式细胞术分选出GFP-细胞群,之后经激活剂曲古抑菌素A(Trichostatin A,TSA)刺激后,再次采用流式细胞术分选出GFP+细胞,并通过有限稀释法制备获得单克隆细胞系。利用流式细胞术及酶联免疫吸附试验(ELISA)分别检测单克隆细胞系在TSA刺激前后的GFP+细胞比例及HIV-1病毒抗原p24;并用Alu-长末端重复序列(LTR)套式聚合酶链反应(Nested PCR)检测单克隆细胞系中HIV-1基因组的整合情况。结果获得了5株HIV-1潜伏感染的Jurkat单克隆细胞系,对这5株单克隆细胞系分别进行激活剂处理,发现无论是GFP表达细胞比例或HIV-1病毒蛋白p24抗原的表达,皆显著高于激活剂处理前的背景表达水平(P<0.05);并能从这5个单克隆细胞系基因组中扩增出针对HIV-1基因组的特异条带。结论已获得的5株单克隆细胞系具有HIV-1潜伏细胞的生物学特点,表明已成功地建立了HIV-1潜伏感染细胞模型。该模型可用于各种药物或激活剂的筛选和检测,也为进一步研究HIV-1潜伏感染机制奠定了工作基础。 Objective To establish a HIV-1 latent infection model in human Jurkat T cell line,which will be used for the mechanism study of HIV-1 latency.Method HIV-1 pseudoviruses which express Enhanced Green Fluorescent Protein（EGFP） were prepared to infect human Jurkat T cells.After sorting out GFP-cell population by Fluorescence-Activated Cell Sorting（FACS）,potential latent clones were screened by the detection of reactivation of GFP after Trichostatin A（TSA） stimulation.These GFP reactivated cell populations were isolated by FACS and cloned to cell lines by limiting dilution.Further test was performed for GFP＋ cell percentage by Flow Cytometry and HIV-1 p24 expression by ELISA before and after stimuli for the clone lines,as well as Alu-LTR nested PCR for HIV-1 genome integration test.Result Five HIV-1 latently infected Jurkat T cell lines were gained,of which GFP and p24 expression were extremely low under basal conditions while significantly raised after TSA stimulation.Alu-LTR nested PCR assay also gained specific band of HIV-1 genomes.Conclusion The 5 clone lines had the biological characteristics of HIV-1 latently infected cells,indicating that HIV-1 latent infection in vitro model was successfully established,which could be used for the screening and detection of drugs or stimuli,as well as for better serving the mechanism study of HIV-1 latency.
作者 李琳 仇超 李亮助 刘爱平 邱趁丽 周明哲 张晓燕 徐建青 朱焕章
机构地区 复旦大学生命科学学院遗传学研究所遗传工程国家重点实验室 复旦大学附属上海市公共卫生临床中心 复旦大学生物医学研究院 复旦大学上海医学院分子病毒学重点实验室 中国疾病预防控制中心传染病预防控制国家重点实验室
出处 《中国艾滋病性病》 CAS 2011年第4期387-390,394,共5页 Chinese Journal of Aids & STD
基金 国家十一五重大专项《艾滋病和病毒性肝炎等重大传染病防治研究项目》资助(课题编号2008ZX10001-006)~~
关键词 艾滋病病毒Ⅰ型 JURKAT T细胞系 绿色荧光蛋白 潜伏感染模型 HIV-1 Jurkat T cell line Green fluorescence protein （GFP） Latent infection model
分类号 R512.91 [医药卫生—内科学]
  • 相关文献

参考文献13

  • 1Sonza S, Crowe SM. Reserviors for HIV infection and their per- sistence in the face of undetectable viral load[J].AIDS Patient Care STDs, 2001, 15(10): 511- 518.
  • 2Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J]. Proc Natl Acad Sci USA, 1997, 94(24): 13193-13197.
  • 3Han YF, Wind-Rotolo M, Yang HC, et al. Experimental approa- ches to the study of HIV-1 latency[J]. Nature Reviews Mierobi- ology, 2007, 5: 95-106.
  • 4Alessandra M, Jill MH, Fabio R. An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency[J]. The Journal of Immunology, 2008, 181: 7713-7720.
  • 5Albert J, Dwayne B, Eric V. HIV reproducibly establishes a la- tent infection after acute infection of T cells in vitro[J]. The EM- BO Journal, 2003, 22(8): 1868-1877.
  • 6仇超,彭虹,黄相刚,任莉,潘翔,邵一鸣,徐建青.携带绿色荧光蛋白基因的单轮感染活性HIV假病毒的建立及其活性检测[J].中华微生物学和免疫学杂志,2006,26(5):394-398. 被引量：14
  • 7Preparation and Titration of HIV-1 Env-Pseudoviruses. Duke Central Immunology Laboratory. 2008. (Accessed at http:// www. hiv. lanl. gov/content/nab-reference-strains/html/Protocol-Preparation-and-Titration-of-HIV-1-Env-Pseuodoviruses-J uly- 2008. pdf).
  • 8Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR[J].Methods, 2009, 47(4): 254-260.
  • 9ODoherty U, Swiggard WJ, Jeyakumar D, et al. A Sensitive, Quantitative Assay for Human Immunodeficiency Virus Type 1 Integration[J]. Journal of Virology, 2002, 76 (21) : 10942 - 10950.
  • 10Bisgrove D, Lewinski M, Bushman F, et al. Molecular mecha- nisms of HIV-1 proviral lateney[J]. Expert Rev Anti Infect T- her, 2005, 3(5): 805-814.

二级参考文献11

  • 1Dong M,Zhang PF,Grieder F,et al.Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.Proc Natl Acad Sci USA,2003,100(6):3345-3350.
  • 2Jordan A,Bisgrove D,Verdin E.HIV reproducibly establishes a latent infection after acute infection ofT cells in vitro.EMBO J,2003,22(8):1868-1877.
  • 3Zhang H,Zhou Y,Alcock C,et al.Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.J Virol,2004,78(4):1718-1729.
  • 4Eckatein DA,Sherman MP,Penn ML,et al.HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells.J Exp Med,2001,194(10):1407-1419.
  • 5He J,Choe S,Walker R,et al.Human immunodeficiency virus type 1 viral protein R(Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.J Virol,1995,69:6705-6711.
  • 6Deng HK,Liu R,Ellmeier W,et al.Identification of a major co-receptor for primary isolates of HIV-1.Nature,1996,381:661-666.
  • 7Mascola JR,Louder MK,Winter C,et al.Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of singleround infection of primary human T cells.J Virol,2002,76(10):4810-4821.
  • 8Gabuzda DH,Lawrence K,Langhoff E,et al.Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.J Virol,1992,66(11):6489-6495.
  • 9He J,Landau NR.Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor.J Virol,1995,69(7):4587-4592.
  • 10Chang LJ,Urlacher V,Iwakuma T,et al.Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.Gene Ther,1999,6(5):715-728.

共引文献13

同被引文献38

  • 1Palmer S, Maldarelli F, Wiegand A,et al. Low-level viremia per- sists for at least 7 years in patients on suppressive antiretroviral therapy[J]. Proc Natl Acad Sci USA, 2008,105 (10), 3879-3884.
  • 2Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possi- bility of a cure for HIV infection[J]. J Intern Med, 2011,270 (6) :550-560.
  • 3Finzi D, Hermankova M, Pierson T,etal. Identification of a res- ervoir for HIV] in patients on highly active antiretroviral therapy [J]. Science, 1997,278(5341) : 1295-1300.
  • 4Wong ]K, Hezareh M, Gtinthard HF,et al. Recovery of replica- tion-competent HIV despite prolonged suppression of plasma vire- mia[J].Science,1997,278(5341) :1291-1295.
  • 5Chun TW, Carruth L, Finzi D,etal. Quantification of latent tis- sue reservoirs and total body viral load in HIV-1 infection[J]. Nature, 1997,387(6629) :183-188.
  • 6Schorder AR, Shinn P, Chen H, etal. HIV1 intergration in the human genome favors active genes and local hotspots[J]. Cell, 2002,110 (4) : 521-529.
  • 7Williams SA, Chen LF, Kwon H, et al. NF-kappaB p50 pro- motes HIV latency through HDAC recruitment and repression of transcriptional initiation [J]. EMBO J, 2006, 25 ( 1 ) : 139- 149.
  • 8Kao SY, Calman AF, Luciw PA, etal. Anti-termination of tran- scription within the long terminal repeat of HIV-1 by tat gene product[J]. Nature, 1987, 330:489-493.
  • 9Yukl S, Pillai S, Li P, et al. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation ac- tivitv[J]. Virology, 2009. 387,98-108.
  • 10Van Lint C, Emiliani S, Ott M,et al. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation [ J ]. EMBO J, 1996, 15 ( 5 ) : 1112-1120. PMID:8605881.

引证文献2

二级引证文献4

中国艾滋病性病
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部